PACE-CME

🔥🔥🔥 #ESCPrev2025 Satellite symposium on “Novel Therapies for Managing Patients with #CardioKidneyMetabolic syndrome & #HeartFailure” Together with @RInciardi & @cristina_gavina is now available for your view on @PACEcme Do not miss it! : bit.ly/3GfTT8Q @escardio

Thanks @PACEcme for covering our #LBCT @escardio #HFA from #FINEARTSHF on the impact of randomization during/shortly post HF hosp on early HF readmission rates. Paper simpub in @JCardFail! Dedicated #REDEFINEHF trial underway to validate these findings. pace-cme.org/congress-cover…

Additional follow-up shows vutrisiran reduces mortality and CV event risks in ATTR-CM Read more: pace-cme.org/news/additiona… #HeartFailure2025 #ATTRCM #CardioTwitter

Is GLP-1RA use harmful or safe in patients with HFrEF and obesity? @VarunSundaram4 shares the results of the PRAISE-HFrEF study. Watch: pace-cme.org/congress-cover… #HeartFailure2025 #HFrEF #Obesity #PRAISEHFrEF #GLP1RA

@mvaduganathan Muthiah Vaduganathan shares the results of the blinded withdrawal of finerenone after long-term treatment in the FINEARTS-HF trial among patients with HFmrEF/HFpEF. Learn more: pace-cme.org/congress-cover… #HeartFailure2025 #HeartFailure #CardioTwitter

Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes - great multidisciplinary discussion @PACEcme @HanCardiomd @_antocannata @MarcoMetra pace-cme.org/programs/cme/s…

Echo essentials for HCM: The heartbeat of diagnosis and treatment Three HCM experts discuss the role of echocardiography and other imaging techniques in the diagnosis and treatment of HCM Learn more: pace-cme.org/programs/cme/e… #HCM #cardiomyopathy

Single LDL-c, hs-CRP, and Lp(a) measurement predicts long-term MACE risk in healthy Europeans Read more: pace-cme.org/news/single-ld… #lipids #inflammation #CVD #CardioTwitter #CVrisk

PACE-CME reports news from the ACC.25 Scientific Session. Follow our news coverage here: pace-cme.org/congress-cover… #ACC25 #cardiology #cardiovascular #diabetes #CVD

Icosapent ethyl in post-CABG patients with diabetes Learn more: pace-cme.org/topics/hyperli… #cardiotwitter #icosapentethyl #CABG #diabetes

Clinical choices in managing LDL-c: Where do novel therapies fit in? Four experts discuss why LDL-c goal attainment is essential. Which options for LDL-c lowering are available, and where do novel therapies fit in? Learn more: pace-cme.org/programs/cme/c… #lipids #CardioTwitter

Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH Stephen Nicholls shares the findings of the phase 3 BROOKLYN study. Watch: pace-cme.org/congress-cover… #CETP #lipids #FH #Obicetrapib #HeFH #AHA24 #BROOKLYN #CardioTwitter

DOAC versus VKA after bioprosthetic valve replacement Read more: pace-cme.org/news/doac-vers… #AHA24 #CardioTwitter #Edoxaban #DOAC #VKA #ENBALV

No effect of anticoagulation on cognitive decline in patients with AF at low risk of stroke Read more: pace-cme.org/news/effect-an… #AHA24 #CardioTwitter #AF #Stroke #Cognitivedecline #BRAINAF

Promising results with oral Lp(a) inhibitor in phase 2 trial Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin was investigated in patients with elevated Lp(a) levels and high CV risk. Watch: pace-cme.org/congress-cover… #AHA24

Tirzepatide reduces HF events in patients with HFpEF and obesity “This is really very exciting news and information. We think it would change the practice of how these patients are treated in the future”, says Milton Packer Watch: pace-cme.org/congress-cover… #AHA2024 #SUMMIT #HF

Phase 3 study results of the APOC3 siRNA plozasiran in patients with familial chylomicronemia syndrome Learn more: pace-cme.org/topics/hyperli… #chylomicronemia #plozasiran #FCS #APOC3

Optimizing care for patients with CKM syndrome: a multidisciplinary approach Learn more: pace-cme.org/programs/cme/o… #CME #CardioTwitter #CKM #Cardiovascular #Kidney #Metabolic

Lessons from global survey on Lp(a) levels in CHD Read more: pace-cme.org/news/lessons-g… #ESCCongress #Lpa #CardioTwitter #CHD #INTERASPIRE

β-blocker therapy cannot be safely withdrawn in stable post-MI patients Read more: pace-cme.org/news/b-blocker… #ESCCongress #ABYSS #postMI #betablocker #Cardiotwitter